China Pharma Holdings, Inc. announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patent Epidemiological research shows that the incidence rate of DED is about 25% to 30%, and the incidence rate of people over 65-year-old is 75% in China According to the Research Report on the Market Status of the Global Dry Eye Disease Drug Industry in 2022(1), the market size of DED drugs in China in 2021 was approximately RMB3.85 billion (approximately US$0.55 billion), resulting a 12.4% year-on-year growth In the field of DED and visual fatigue, this product will fill in the market gap of medical therapeutic apparatus the company have established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years; which will strongly support the launch and promotion of this device Dry eye disease (DED) refers to the general term of a variety of diseases related to abnormal tear quality, quantity, or dynamics, accompanied by eye discomfort (dry eyes, tingling, burning, gritty feeling, etc.) and/or ocular surface tissue lesions. Which may be caused by any reason (including aging, wearing contact lenses, certain drugs, eye diseases, other diseases, or environmental factors).